271 related articles for article (PubMed ID: 29860563)
1. Outcome of gastrointestinal graft-versus-host disease according to the treatment response.
Tamaki M; Nakasone H; Misaki Y; Yoshimura K; Gomyo A; Hayakawa J; Kusuda M; Akahoshi Y; Ishihara Y; Kawamura K; Tanihara A; Sato M; Terasako-Saito K; Kameda K; Wada H; Kikuchi M; Kimura SI; Kako S; Kanda Y
Ann Hematol; 2018 Oct; 97(10):1951-1960. PubMed ID: 29860563
[TBL] [Abstract][Full Text] [Related]
2. Crypt loss is a marker of clinical severity of acute gastrointestinal graft-versus-host disease.
Melson J; Jakate S; Fung H; Arai S; Keshavarzian A
Am J Hematol; 2007 Oct; 82(10):881-6. PubMed ID: 17570511
[TBL] [Abstract][Full Text] [Related]
3. Acute gastrointestinal graft-versus-host disease in pediatric patients: serum albumin on day 5 from initiation of therapy correlates with nonrelapse mortality and overall survival.
Goussetis E; Paisiou A; Kitra V; Peristeri I; Vessalas G; Stefanaki K; Panayotou I; Giamaiou K; Kontou E; Kitzoni M; Dimopoulou MN; Karkelis S; Kafritsa Y; Rapsomaniki E; Papassotiriou I; Tsirigotis P; Roma E; Graphakos S
Biol Blood Marrow Transplant; 2011 Jul; 17(7):1058-66. PubMed ID: 21073975
[TBL] [Abstract][Full Text] [Related]
4. Late Gastrointestinal Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Adults.
Sung AD; Hassan S; Cardona DM; Wild D; Nichols KR; Mehdikhani H; Balmadrid B; Detweiler CJ; Shealy M; Cirrincione C; Li Z; Poleski M; Dalton TE; Siamakpour-Reihani S; Chao NJ; Sullivan KM
Biol Blood Marrow Transplant; 2018 Apr; 24(4):734-740. PubMed ID: 29246821
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of intractable gastrointestinal tract graft-vs-host disease with oral beclomethasone dipropionate in pediatric and young adult patients: Case reports.
Akahane K; Watanabe A; Somazu S; Harama D; Shinohara T; Kasai S; Oshiro H; Goi K; Hasuda N; Ozawa C; Sugita K; Inukai T
Medicine (Baltimore); 2022 Mar; 101(11):. PubMed ID: 35356922
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Fecal Microbiota Transplantation for Grade IV Steroid Refractory GI-GvHD Patients: Interim Results From FMT2017002 Trial.
Zhao Y; Li X; Zhou Y; Gao J; Jiao Y; Zhu B; Wu D; Qi X
Front Immunol; 2021; 12():678476. PubMed ID: 34220825
[TBL] [Abstract][Full Text] [Related]
7. Oral beclomethasone dipropionate for the treatment of gastrointestinal acute graft-versus-host disease (GVHD).
Castilla C; Pérez-Simón JA; Sanchez-Guijo FM; Díez-Campelo M; Ocio E; Pérez-Persona E; López-Villar O; Vazquez L; Caballero D; San Miguel JF
Biol Blood Marrow Transplant; 2006 Sep; 12(9):936-41. PubMed ID: 16920559
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic stem cell transplantation as treatment for heavily treated, refractory acute graft-versus-host disease after HLA-mismatched stem cell transplantation.
Ikegame K; Yoshihara S; Taniguchi Y; Kaida K; Inoue T; Okada M; Taniguchi K; Hasei H; Tamaki H; Fujioka T; Kato R; Soma T; Ogawa H
Exp Hematol; 2011 Aug; 39(8):880-90. PubMed ID: 21689724
[TBL] [Abstract][Full Text] [Related]
9. Endoscopic and Histological Findings Are Predicted by Fecal Calprotectin in Acute Intestinal Graft-Versus-Host-Disease.
Adam B; Koldehoff M; Ditschkowski M; Gromke T; Hlinka M; Trenschel R; Kordeals L; Steckel NK; Beelen DW; Liebregts T
Dig Dis Sci; 2016 Jul; 61(7):2019-26. PubMed ID: 26995779
[TBL] [Abstract][Full Text] [Related]
10. Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract.
Ganetsky A; Frey NV; Hexner EO; Loren AW; Gill SI; Luger SM; Mangan JK; Martin ME; Babushok DV; Drobyski WR; Smith J; Timlin C; Freyer CW; Stadtmauer EA; Porter DL
Bone Marrow Transplant; 2019 Feb; 54(2):212-217. PubMed ID: 29795429
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of intra-arterial steroid infusions in patients with steroid-resistant gastrointestinal acute graft-versus-host disease.
Nishimoto M; Koh H; Hirose A; Nakamae M; Nakane T; Hayashi Y; Okamura H; Yoshimura T; Koh S; Nanno S; Nakashima Y; Takeshita T; Yamamoto A; Sakai Y; Nishida N; Matsuoka T; Miki Y; Hino M; Nakamae H
Exp Hematol; 2015 Dec; 43(12):995-1000. PubMed ID: 26303639
[TBL] [Abstract][Full Text] [Related]
12. Immunological effects in patients with steroid-refractory graft-versus-host disease following treatment with basiliximab, a CD25 monoclonal antibody.
Chakupurakal G; García-Márquez MA; Shimabukuro-Vornhagen A; Theurich S; Holtick U; Hallek M; Scheid C; von Bergwelt-Baildon M
Eur J Haematol; 2016 Aug; 97(2):121-7. PubMed ID: 26492560
[TBL] [Abstract][Full Text] [Related]
13. Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation.
Massenkeil G; Rackwitz S; Genvresse I; Rosen O; Dörken B; Arnold R
Bone Marrow Transplant; 2002 Dec; 30(12):899-903. PubMed ID: 12476283
[TBL] [Abstract][Full Text] [Related]
14. Long-term use of oral beclomethasone dipropionate for the treatment of gastrointestinal graft-versus-host disease.
Iyer RV; Hahn T; Roy HN; Battiwalla M; Cooper M; Anderson B; Paplham P; Brown K; Bambach B; Segal BH; McCarthy PL
Biol Blood Marrow Transplant; 2005 Aug; 11(8):587-92. PubMed ID: 16041308
[TBL] [Abstract][Full Text] [Related]
15. The use of oral beclomethasone dipropionate in the treatment of gastrointestinal graft-versus-host disease: the experience of the Fukuoka blood and marrow transplantation (BMT) group.
Takashima S; Eto T; Shiratsuchi M; Hidaka M; Mori Y; Kato K; Kamezaki K; Oku S; Henzan H; Takase K; Matsushima T; Takenaka K; Iwasaki H; Miyamoto T; Akashi K; Teshima T
Intern Med; 2014; 53(12):1315-20. PubMed ID: 24930650
[TBL] [Abstract][Full Text] [Related]
16. Oral beclomethasone dipropionate for the treatment of gastrointestinal chronic graft-versus-host disease.
Villanueva FN; Pérez-Simón JA; Silva FF; Caballero-Velázquez TT; Sánchez-Guijo FF; Cañizo CC; Vázquez LL; Caballero DD; San Miguel JF
Biol Blood Marrow Transplant; 2009 Oct; 15(10):1331-6. PubMed ID: 19747642
[TBL] [Abstract][Full Text] [Related]
17. Basiliximab for the treatment of steroid-refractory acute graft-versus-host disease after unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation.
Wang JZ; Liu KY; Xu LP; Liu DH; Han W; Chen H; Chen YH; Zhang XH; Zhao T; Wang Y; Huang XJ
Transplant Proc; 2011 Jun; 43(5):1928-33. PubMed ID: 21693302
[TBL] [Abstract][Full Text] [Related]
18. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E;
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
[TBL] [Abstract][Full Text] [Related]
19. The use of basiliximab-infliximab combination for the treatment of severe gastrointestinal acute GvHD.
Nadeau M; Perreault S; Seropian S; Foss F; Isufi I; Cooper DL
Bone Marrow Transplant; 2016 Feb; 51(2):273-6. PubMed ID: 26479982
[TBL] [Abstract][Full Text] [Related]
20. Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?
Ji YS; Lee MS; Min CW; Park SK; Kim SH; Yun J; Kim HJ; Kim KH; Kim CK; Lee KT; Won JH; Hong DS
Korean J Intern Med; 2016 Jul; 31(4):750-61. PubMed ID: 27017944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
